Kurum Yazarı "Sevindik, Ömür Gökmen" WoS İndeksli Yayınlar Koleksiyonu İçin Listeleme
-
Acute myeloid leukemia in elderly, unfit patients: Analysis of Turkish AML prospective registry database, on behalf of acute leukemia working group of Turkish society of hematology
Merih Urlu, Selin; Cengiz Seval, Güldane; Erdoğan Yücel, Elçin; Mehtap, Özgür; Yenihayat, Emel Merve; Polat, Merve Gökçen; Malkan, Ümit Yavuz; Karakuş, Volkan (American Society of Hematology, 2023)Objective: Low dose Ara-C and hypomethylating agents (HMAs) - decitabine (DEC) and azacitidine (AZA) - have made it possible to treat more elderly patients with acute myeloid leukemia (AML). Both HMAs demonstrated efficacy ... -
Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
Sevindik, Ömür Gökmen; Gemici, Aliihsan; Usta, Furkan Selim; Çakır, Aslı; Sadri, Sevil; Bekoz, Hüseyin; Sargın, Fatma Deniz (The American Society of Hematology, 2019)Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. ... -
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür Gökmen (American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Sevindik, Ömür Gökmen; Chen, Chang; Yang, Jing; Farooqui, Mohammed Z. H.; Paszkiewicz-Kozik, Ewa (Lippincott Williams & Wilkins, 2023)... -
A case series of CML patients who were presented with isolated thrombocytosis
Karakuş, Volkan; Aslan, Vedat; Parça, Güleycan; Sevindik, Ömür Gökmen; Keklik Karadağ, Fatma; Kurtoğlu, Erdal; Saydam, Güray (American Society of Hematology, 2022)Per WHO 2016 and 2022 (5th ed.) myeloproliferative disease guidelines, Chronic Myeloid Leukemia (CML) is classified under two major groups according to the presence of bcr-abl translocation; these groups require different ... -
Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri (NLM (Medline), 2022)Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly ... -
Clinical outcomes and treatment patterns of primary central nervous system lymphoma: Multicenter retrospective analysis
Güven, Serkan; Yavuz, Boran; Erdoğan Yücel, Elçin; Karataş, Aylin Fatma; Özsan, Güner Hayri; Demirkan, Fatih; Ündar, Bülent; Özcan, Mehmet Ali; Kiper, Hatice Demet; Çetintepe, Tuğba; Göçer, Mesut; Kurtoğlu, Erdal; Balık Aydın, Berrin; Sevindik, Ömür Gökmen; Yiğit Kaya, Süreyya; Alacacıoğlu, İnci (Kare Publishing, 2023)Objectives: Primary central nervous system lymphoma (PCNSL) is a rare malignant disease with poor prognosis. Its low incidence leads to challenges in decision-making for treatment. As a matter of fact, there is still no ... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül (American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma
Solmaz, Şerife; Uzun, Özcan; Sevindik, Ömür Gökmen; Demirkan, Fatih; Özcan, Mehmet Ali; Özsan, Güner Hayri; Alacacıoğlu, İnci (John Wiley and Sons Inc, 2023)Introduction In multiple myeloma cases, a variety of prognostic parameters have been identified, which contain the Durie-Salmon classification and the international staging system (ISS) that takes the serum ss2 microglobulin ... -
Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience
Kılıç Güneş, Ebru; Yiğit Kaya, Süreyya; Yaman, Fatih; Yeniay, Mustafa Kemal; Vural, Kurtuluş; Cömert, Melda; Sevindik, Ömür Gökmen; Andıç, Neslihan; Dağdaş, Simten; Nizam Özen, İlknur; Kaynar, Leylagül; Yavaşoğlu, Filiz; Özet, Gülsüm; Karakuş, Volkan; Aylı, Meltem (2024)Introduction: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this ... -
First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Lippincot Williams & Wilkins, 2022)Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can ... -
Gilteritinib (XOSPATA (R)) in Turkey: Early access program results
Doğu, Mehmet Hilmi; Tekgündüz, Ali İrfan Emre; Deveci, Burak; Korkmaz, Gülten; Cömert, Melda; Sevindik, Ömür Gökmen; Yokuş, Osman; Serin, İstemi (Mattioli 1885, 2023)Background And Objectives: Gilteritinib (XOSPATA (R), Astellas) is a type I oral FLT3 inhibitor, a tyrosine kinase AXL inhibitor, involved in both c-Kit and FMS-like tyrosine kinase 3 (FLT3) resistance. In the phase 3 ... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data
Birtaş Ateşoğlu, Elif; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Ferhanoğlu, Burhan (Wiley, 2023)Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and a single CD3-binding fragment. Encouraging response and survival rates were recently reported in a pivotal phase II expansion ... -
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
Pınar, İbrahim Ethem; Çelik, Serhat; Polat, Merve Gökçen; Karataş, Aylin Fatma; Doğan, Ali; Iltar, Utku; Cengiz Seval, Güldane; Sevindik, Ömür Gökmen (American Society of Hematology, 2023)Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ... -
Inherited transmission of the CSF3R T618I mutation: A familial report
Serin, istemi; Cinli, Tahir Alper; Tunç, Sertaç; Kaynar, Leylagül; Sevindik, Ömür Gökmen; Yokuş, Osman (Springer, 2023)To the editor, Chronic neutrophilic leukemia (CNL) is a rare, break cluster region-Abelson 1 (BCR-ABL1) negative myeloproliferative neoplasm, which is characterized by mature neutrophilic proliferation with neutrophilic ... -
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; Yıldız, İpek; Gedük, Ayfer; Harmandali, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kaşar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (American Society of Hematology, 2021)... -
Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study
Mateos, Maria-Victoria; Rodriguez Otero, Paula; Koh, Youngil; Martinez-Lopez, Joaquin; Parmar, Gurdeep; Prince, H. Miles; Quach, Hang; Ribas, Paz; Hermansen, Emil; Hungria, Vania T. M.; Kalayoğlu Beşışık, Sevgi; Kim, Jin Seok; Leleu, Xavier; Peceliunas, Valdas; Schjesvold, Fredrik; Sevindik, Ömür Gökmen; Lavrova, Tatiana; Dubin, Franck; Devisme, Christine; Lepine, Lucie; Ghobrial, Irene (American Society of Hematology, 2022)Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients ... -
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Lavie, David; Timmerman, John; Sanz, Ramon Garcia; Kim, Won Seog; Kim, Tae Min; Avigdor, Abraham; Dierickx, Daan; Jagadeesh, Deepa; Herrera, Alex Francisco (Lippincott Williams & Wilkins, 2023)...